Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

NCT02371408 is registered in ClinicalTrials.gov with Pharco Pharmaceuticals as lead sponsor.

NCT NCT02371408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02371408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Lead sponsor
Pharco Pharmaceuticals
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 31, 2015
Completion date
April 30, 2016
Enrollment
300 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c